Xie Jing-Tian, Mehendale Sangeeta R, Li Xinmin, Quigg Richard, Wang Xiaoyu, Wang Chong-Zhi, Wu Ji An, Aung Han H, A Rue Paul, Bell Graeme I, Yuan Chun-Su
Tang Center for Herbal Medicine Research, The Pritzker School of Medicine, The University of Chicago, MC 4028, IL 60637, USA.
Biochim Biophys Acta. 2005 Jun 10;1740(3):319-25. doi: 10.1016/j.bbadis.2004.10.010. Epub 2004 Nov 5.
We evaluated the anti-diabetic effects of ginsenoside Re in adult male C57BL/6J ob/ob mice. Diabetic ob/ob mice with fasting blood glucose levels of approximately 230 mg/dl received daily intraperitoneal injections of 7, 20 and 60 mg/kg ginsenoside Re for 12 consecutive days. Dose-related effects of ginsenoside Re on fasting blood glucose levels were observed. After the 20 mg/kg treatment, fasting blood glucose levels were reduced to 188+/-9.2 and 180+/-10.8 mg/dl on Day 5 and Day 12, respectively (both P<0.01 compared to vehicle group, 229+/-9.5 and 235+/-13.4 mg/dl, respectively). The EC(70) of ginsenoside Re was calculated to be 10.3 mg/kg and was used for subsequent studies. Consistent with the reduction in blood glucose, there were significant decreases in both fed and fasting serum insulin levels in mice treated with ginsenoside Re. With 12 days of ginsenoside treatment, glucose tolerance of ob/ob mice increased significantly, and the area under the curve for glucose decreased by 17.8% (P<0.05 compared to vehicle treatment). The hypoglycemic effect of the ginsenoside persisted even at 3 days of treatment cessation (blood glucose levels: 198+/-13.1 with ginsenoside treatment vs. 253+/-20.3 mg/dl with vehicle, P<0.01). There were no significant changes in body weight or body temperature. Preliminary microarray analysis revealed differential expression of skeletal muscle genes associated with lipid metabolism and muscle function. The results suggest that ginsenoside Re may prove to be useful in treating type 2 diabetes.
我们评估了人参皂苷Re对成年雄性C57BL/6J ob/ob小鼠的抗糖尿病作用。空腹血糖水平约为230 mg/dl的糖尿病ob/ob小鼠连续12天每天腹腔注射7、20和60 mg/kg人参皂苷Re。观察到人参皂苷Re对空腹血糖水平有剂量相关效应。在20 mg/kg治疗后，第5天和第12天的空腹血糖水平分别降至188±9.2和180±10.8 mg/dl（与溶媒组相比，二者P均<0.01，溶媒组分别为229±9.5和235±13.4 mg/dl）。计算得出人参皂苷Re的半数有效浓度（EC70）为10.3 mg/kg，并用于后续研究。与人参皂苷Re治疗小鼠血糖降低一致，喂食和空腹血清胰岛素水平均显著下降。经过12天的人参皂苷治疗，ob/ob小鼠的葡萄糖耐量显著增加，葡萄糖曲线下面积下降了17.8%（与溶媒治疗相比，P<0.05）。即使在停药3天时，人参皂苷的降血糖作用仍然存在（血糖水平：人参皂苷治疗组为198±13.1，溶媒组为253±20.3 mg/dl，P<0.01）。体重和体温无显著变化。初步微阵列分析显示，与脂质代谢和肌肉功能相关的骨骼肌基因存在差异表达。结果表明，人参皂苷Re可能对治疗2型糖尿病有用。
